LYON, FRANCE—Once-daily oral teriflunomide 14 mg significantly reduced the annualized relapse rate and slowed progression of disability in patients with relapsing forms of multiple sclerosis (MS) compared with placebo, according to data presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). In addition, the proportion of patients treated with teriflunomide who were relapse-free was significantly higher compared with placebo.
Ludwig Kappos, MD, Chair of Neurology, University Hospital Basel, Switzerland, and colleagues presented the results of TOWER (Teriflunomide Oral in people With relapsing multiplE scleRosis), the second phase III randomized, double-blind trial of teriflunomide. “The TOWER study results are consistent with the phase III TEMSO data, both in terms of the effect on progression of disability and the manageable safety profile of teriflunomide,”
said Dr. Kappos.
TOWER enrolled 1,169 patients with relapsing-remitting MS across 26 countries and compared 7 mg or 14 mg once-daily oral teriflunomide with placebo.